Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00482430 |
The purpose of this study is to determine the safety and effectiveness of an investigational drug for the treatment of cognitive impairment in patients with schizophrenia.
Condition | Intervention | Phase |
---|---|---|
Paranoid Schizophrenia Schizophrenia |
Drug: MK0557 Drug: Comparator: Placebo (unspecified) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia |
Enrollment: | 50 |
Study Start Date: | September 2007 |
Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1
MK0557 10mg tablet qd, crossing over to MK0557 Pbo tablet qd.
|
Drug: MK0557
MK0557 10mg tablet qd for a 15-wk treatment period
Drug: Comparator: Placebo (unspecified)
MK0557 Pbo tablet qd for a 15-wk treatment period
|
2
MK0557 Pbo tablet qd, crossing over to MK0557 10mg tablet qd.
|
Drug: MK0557
MK0557 10mg tablet qd for a 15-wk treatment period
Drug: Comparator: Placebo (unspecified)
MK0557 Pbo tablet qd for a 15-wk treatment period
|
Ages Eligible for Study: | 21 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences ) |
Study ID Numbers: | 2007_520, MK0557-027 |
Study First Received: | May 31, 2007 |
Last Updated: | November 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00482430 |
Health Authority: | Malaysia: Ministry of Health |
Undifferentiated schizophrenia Residual schizophrenia |
Schizophrenia Schizophrenia, Paranoid Mental Disorders Psychotic Disorders Schizophrenia and Disorders with Psychotic Features |